CONTACT US: Contact info
|
Citation |
Mosiołek A, Mosiołek J. Int. J. Environ. Res. Public Health 2023; 20(3). |
|
Copyright |
(Copyright © 2023, MDPI: Multidisciplinary Digital Publishing Institute) |
|
DOI |
|
PMID |
36767478 |
|
PMCID |
|
|
Abstract |
Psychotic disorders are associated with significant impairment in functioning, and their treatment remains a great therapeutic challenge. Patients are at a higher risk of suicide and premature mortality. Biomarkers, such as brain-derived neurotrophic factor (BDNF), play a vital role in neurotransmission and neurodevelopment. Decreased levels of BDNF alter neuronal signaling and cause the appearance of symptoms such as the impairment of working memory. A literature search was performed using the PubMed data base. Following the inclusion and exclusion criteria, 24 original articles were selected. We collected available data showcasing the influence of antipsychotic and non-pharmacological treatments, in patients suffering from psychotic disorders, on clinical conditions and BDNF levels in serum or plasma. In this review, we outline emerging data regarding the influence of different antipsychotic drugs and non-pharmacological treatment methods on BDNF and discuss their role as predictors of treatment outcome. Most studies conducted with antipsychotics saw an increase in BDNF levels; however, no positive correlation between change in BDNF and PANSS scores was observed. Studies based on non-pharmacological methods varied based on the treatment applied. Therefore, it is difficult to draw definite conclusions. Language: en |
|
Keywords |
*Antipsychotic Agents/therapeutic use; *Psychotic Disorders/drug therapy; *Schizophrenia/drug therapy; Biomarkers; Brain-Derived Neurotrophic Factor; brain-derived neurotrophic factor/BDNF; Humans; psychotic disorders; schizophrenia |